INTRODUCTION
Smoking remains the most preventable cause of death worldwide. In the U.S. alone, tobacco use accounts for 480,000 premature deaths every year [1] . Cancer patients and survivors face even greater risk from smoking than the general population. The 2014 Surgeon General's report emphasized that continued smoking after a cancer diagnosis adversely influences health outcomes and overall survival, but quitting after diagnosis can improve cancer prognosis, overall health, and quality of life [2] . The Clinical Practice Guidelines for Treating Tobacco Use and Dependence (TTUD) from the Public Health Service emphasize assessment and documentation of tobacco use in all clinical care encounters, along with referral to evidence-based treatments (including pharmacotherapy, nicotine replacement, and behavioral treatments, most of which are safe and efficacious in cancer patients; Table 1 • Nicotine patch + short-acting NRT (lozenge, gum, nasal spray, inhaler) • Begin with 21 mg nicotine patch. If it is not effective, consider adding an additional patch to increase dose to 35-42 mg • Short-acting NRT can be taken every 1-2 hours as needed for cravings with a gradual dose reduction over 10 weeks Duration is 12 weeks (although treatment can be extended up to 6 months to 1 year to promote continued cessation)
• Blood nicotine levels from combination NRT are significantly less than from smoking cigarettes • Combination NRT is well tolerated and nicotine toxicity is rare and transient, even when used with continued smoking • Patients commonly under-dose with combination NRT and nicotine overdose is rare, but possible and usually short-lived
Varenicline (Chantix) a,b
• Initiate dosing 1-2 weeks prior to quitting • Days 1-3: 0.5 mg orally once daily • Days 4-7: 0.5 mg orally twice daily • Weeks 2-12: 1 mg orally twice daily, if tolerated Duration is 12 weeks (although treatment can be extended up to 6 months to 1 year to promote continued cessation)
• Nausea is a common side effect and may need to be managed for cancer patients, especially during chemotherapy • Although rare, providers should monitor for the development or worsening of serious neuropsychiatric issues (i.e., depression and suicidal ideation/behavior) including in those without a previous history and discontinue if signs occur • Review the Manufacturer Black Box Warning and weigh benefits of immediate smoking cessation and risks of increased hostility, depression, or suicidal behavior • Contraindicated for patients with brain metastases because of seizure risk Bupropion (sustained release) and NRT
• Initiate dosing 1-2 weeks prior to quitting • Adjust dose for hepatic insufficiency • Day 1-3: 150 mg orally once daily • Day 4-12 weeks: 150 mg orally twice daily, if tolerated • Maximum dose is 300 mg/day Duration is 7-12 weeks (although treatment can be extended up to 6 months to 1 year to promote continued cessation)
• Although rare, providers should monitor for the development or worsening of serious neuropsychiatric issues (i. Despite the guidelines and availability of evidencebased cessation approaches, smoking rates remain high among individuals diagnosed with cancer [5] , and cancer centers have been slow to establish tobacco treatment services. In their survey of 58 National Cancer Institute (NCI)-designated cancer centers, Goldstein and colleagues found that only 58.6% reported TUT within their center (20.7% reported external TUT services and 20.7% had no TUT services) [6] . Only 38% of centers assessed tobacco as a vital sign and 48% had designated TUT personnel. Centers suboptimally implemented recommended clinician-oriented TUT practices: only 35% noted adequate training of clinicians and 9% provided regular feedback to clinicians about their cessation referral rates. Based on these findings, the authors recommended that cancer centers should institutionally fund internal TUT programs and implement quality improvement efforts and that NCI should take a more active role in TUT provision [6] . The NCI has issued a call to action for all cancer centers to address smoking cessation for cancer patients and survivors [7] and recently offered supplemental funds from the Cancer Moonshot Initiative to facilitate implementation of evidence-based TUT programs at NCI-designated cancer centers [8] .
The TTUD clinical practice guidelines note that all health care professionals, including oncology care clinicians (OCCs), should provide at least brief intervention to every tobacco user. Data from general health care settings show that advice from a clinician is influential; even 3 minutes of advice and smoking cessation counseling may increase the odds of abstinence by 30%-50%, and meta-analyses show that advice from clinicians to stop smoking significantly increases quit rates [9, 10] . The ability to facilitate appropriate referrals and coordinate hand-offs is also important; direct introduction to a TUT professional (so-called "warm handoffs") have been shown to increase enrollment in tobacco treatment programs over electronic referrals [11] . At each visit, clinicians should follow the 5As model of brief cessation intervention: (1) Ask all patients about their tobacco use; (2) Advise smokers to quit; (3) Assess smokers' willingness to quit; (4) Assist smokers with cessation; and (5) Arrange follow-up contact to prevent relapse [9] . The 5As were formulated to be easily implemented across diverse clinical settings and patient populations and were designed with the understanding of busy clinic schedules [9] . For providers less comfortable with TUT delivery or with substantial time constraints, the 5As can be abbreviated to AAR: Ask, Advise, and Refer [9] .
For patients receiving cancer care, an important step in successful TUT hinges on oncology care clinicians' consistent and effective use of the 5As or AAR. OCCs are trusted sources of information and guidance for cancer patients [12] . The combination of patients' advice-seeking and increased motivation to quit make the oncologic context a powerful opportunity to engage in conversations about smoking cessation [13, 14] . A cancer diagnosis may serve as a "teachable moment" in which motivation for and interest in tobacco cessation increase [15] . The entire period from diagnosis through survivorship has been described as a "window of opportunity" through which clinicians can intervene and assist cancer patients in the tobacco cessation process [16] . Patients who continue to smoke after a cancer diagnosis often do not ask their OCCs for assistance because of stigma and guilt [17] . Therefore, clinicians play a critical role in initiating conversations about the risks of continued smoking after a cancer diagnosis, advising patients to quit, prescribing treatment, or providing referrals. Because relapse is common in this population, clinicians also play important roles in assisting patients in maintaining abstinence and preventing relapse [13] .
REVIEW OBJECTIVES
This scoping review covers oncology care clinicians' assessment and treatment of tobacco use among cancer patients and survivors through the framework of the 5As. We included papers that report data from multiple sources, including OCC self-report, cancer patient/survivor report, clinic or health system representative report, and objective data sources such as electronic medical records or billing codes. For the purpose of this review, we defined OCC as any clinician who provides cancer treatment, follow-up, or supportive care in the cancer trajectory. Based on more recent understanding of tobacco and cessation in the context of oncology and the release of the 2008 update to the "Treating Tobacco Use and Dependence" Clinical Practice Guideline, which established an expectation of standard tobacco treatment practices, we focused primarily on the last 10 years of research, addressing patient-, clinician-, and system-level barriers to providing tobacco cessation advice and treatment to cancer patients, as well as interventions to increase clinician adherence to practice guidelines.
MATERIALS AND METHODS
We conducted a scoping review in accordance with the methodological framework for scoping reviews published by Arksey and O'Malley [18] and advanced notably by Levac et al. [19] , which includes guidance on identifying the research question, searching for and selecting relevant studies, charting the data, and summarizing the results.
Search Strategy
PubMed and PsycINFO electronic databases were initially searched in December 2016, with an updated search conducted on August 1, 2017, for potentially eligible studies published up to July 2017. The following key search words were used in different combinations: "teachable moment," "providers," "smoking cessation," "oncology," "tobacco," "cancer," and "5As" (e.g., [oncology OR cancer] and [smoking OR tobacco] and [provider OR clinician]). References were crosschecked, and all available abstracts were reviewed to obtain articles of interest. Articles were limited to human subjects, those written in English and published between 2006 and 2017.
Eligibility Criteria
To be included, studies were required to be empirical research focused on OCCs and to include data on at least one of following: (1) quality and/or frequency of conversations about tobacco use or cessation with adult cancer patients or survivors, (2) barriers in discussing tobacco use with cancer patients and survivors, and (3) interventions to increase the quality and/or frequency of tobacco treatment for cancer patients or survivors. Empirical studies of clinical practice guideline adherence included surveys and/or qualitative interviews completed by cancer patients, survivors, OCCs, cancer center administrators, and/or reviews of medical records. Letters, conference abstracts, editorials, opinion papers, and reviews that did not report on unique data were excluded. Based on U.S.-specific guidelines, we only included papers reporting on data in the U.S. In the initial exploratory searches, we noted a limited number of studies explicitly assessing OCC adherence to all of the 5A components. To broaden the scope of the review, studies that assessed individual aspects or subsets of the 5As (e. g., tobacco use documentation, assessment, and counseling) and/or were not specifically described within the 5A or AAR frameworks were included (in the latter case, authors classified outcomes within the appropriate framework components). All authors were experienced in narrative, scoping, and systematic review methods. The first author (S.P.) conducted the literature search with support from the full team (J.S. and H.H). Abstracts of identified articles were reviewed against inclusion criteria (S.P.), and studies were excluded if eligibility criteria were not clearly met. If a paper could not be excluded based on the abstract, the full article was reviewed. A spreadsheet was designed and used by S.P. to aid in data extraction and charting. Coauthors (J.S. and H.H.) then reviewed the results of the article selection and data extraction process, and results were discussed as a team to describe emergent themes in the literature and to resolve any disagreements. Data collected from each article included authors and author affiliations, title, journal, year of publication, study setting, eligibility criteria, participants (patient/ OCCs/administrators), sample size, reference to OCC assessment and treatment of tobacco use among cancer patients in routine practice settings, barriers to tobacco assessment and treatment, and any outcomes from interventions designed to improve OCC provision of TUT.
RESULTS

Literature Search Results
The initial search yielded 922 articles, based on review of abstracts; 42 full-text articles were then accessed for eligibility, yielding 12 eligible articles. Three additional papers that were all eligible were identified after hand-searching the reference sections of relevant papers (Fig. 1 ). In total, 15 papers were included in this scoping review, but 2 papers (by colleagues, 2013 and reported on the same survey data, resulting in 14 unique studies (Table 2 ). Although the 5As or AAR were mentioned in the majority of the studies reviewed, only one (by Simmons and colleagues) explicitly labeled each A. Therefore, the remaining studies required some amount of translation into the 5A/AAR framework (e.g., deciding that prescribing tobacco cessation medication falls under "Assist," despite the fact that the authors of the original studies did not describe it that way explicitly). Of the 14 unique studies, 3 focused on all 5As, 7 focused on a subset of the 5As, and 4 addressed only a single A or discussed adherence to clinical practice guidelines broadly, with terms such as "providers discussed tobacco cessation" or "patients were counseled on smoking cessation."
Seven papers discussed barriers to 5A adherence. The papers used different approaches to examine clinician adherence to clinical practice guidelines, with seven studies using clinician report, five patient report, four Electronic Health Record (EHR) or billing codes, and two using report from clinic representatives or administrators. Eight of the fourteen studies collected data at academic medical centers, one study collected data from a community medical center, and five collected national/regional data from a variety of urban and rural practice settings, including private practice, academic institutions, managed care, and multispecialty groups. The majority of included studies (eight) focused specifically on OCCs treating tobacco-related cancers such as lung, head and neck, and genitourinary, whereas the rest studied the behavior of OCCs treating patients with a variety of tumor types, including those related and unrelated to tobacco use.
Frequency of the 5As in Oncology Settings
Ask All Patients About Their Tobacco Use
Oncology Care Clinicians were most likely to adhere to the first A, "ask all patients about tobacco use." Across the seven relevant studies, 77%-100% of OCCs routinely asked about tobacco use at a patient's initial visit [13, 20] . However, in the three studies that addressed follow-up, tobacco assessment rates dropped at subsequent visits [13, [21] [22] [23] . For example, Weaver and colleagues found that OCCreported rates of smoking assessment dropped from 82.4% to 60.8% (for current smokers) and 42.5% (for recent quitters) at follow-up visits [22] . EHR review confirmed provider report in this study, with smoking status documentation rates ranging from 60% to 95% at patients' initial visit and dropping to 5%-80% at subsequent visits [22] . Low rates of tobacco assessment and documentation may be due in part to lack of system-level infrastructure. For example, in their survey of 15 Wisconsin cancer clinics, Adsit and colleagues found that only 10 clinics collect smoking status and 8 assess for all tobacco use at every visit [25] .
Advise Smokers to Quit
Among 10 reviewed studies that focused on this aspect, results indicated that 62%-100% of OCCs sometimes or always encourage current smokers to quit [20, 28] . Delivery of this advice was variable and not always detailed or evidence-based [9] . For example, in a survey of cancer patients smoking at diagnosis, 62% were advised to quit by an OCC, but only 44% reported being informed of the specific dangers of continued smoking during treatment [26] . Semistructured interviews noted that although providers feel confident in delivering their message to quit smoking, patients do not perceive their clinicians' messages as particularly strong or helpful. When asked about the effectiveness of clinician messaging, patients reported that they would prefer a more balanced approach that emphasized
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Assess Smokers' Willingness to Quit
Among the reviewed studies, only four documented adherence to "assessing" willingness to quit. In these studies, OCCs' rates of routinely assessing willingness to quit ranged from 46% to 80% [20, 21, 23, 25] .
Assist Smokers with Cessation
Across nine of the reviewed studies, 20%-62% of OCCs routinely assist patients with tobacco cessation (e.g., discussing tobacco cessation or suggesting at least one treatment) [20] [21] [22] [23] [24] [25] [27] [28] [29] . Rates of actively treating (prescribing medication or referring to appropriate treatment) are consistently low (generally <40%) based on patient and provider report, billing codes, and EHR documentation [20-24, 30, 31] . For example, in an analysis of billing claims from over 34 million enrollees with newly diagnosed genitourinary cancers and noted tobacco use disorder, only 5.3% had claims for smoking cessation interventions [30] . When treatment was discussed, varenicline or bupropion and nicotine replacement therapy were recommended more frequently than psychological treatments in all but two reviewed studies [20, 22, 25, 27, 28, 30] .
Arrange Follow-Up Contact to Prevent Relapse
Six studies examined OCC follow-up contact to prevent relapse, with rates ranging widely across reports (3.6%-72%) [20] [21] [22] [23] [24] . Studies examining whether OCCs arranged a follow-up call or visit specifically to assess quitting progress showed lower rates compared with studies that simply documented whether OCCs ask about smoking at subsequent appointments (3.6%-11.7% vs. 55%-71%) [20] [21] [22] [23] [24] . Oncology care clinicians were more likely to ask smokers if they have quit at a follow-up appointment than to ask a previously abstinent smoker if they have relapsed (70%-72% vs. 55%-62.7%) [21, 23] .
Barriers to Providing Tobacco Assessment and Treatment
Clinician-Level Factors
Despite generally favorable attitudes toward TUT for cancer patients, more than half of OCCs in four different 
System-Level Factors
Across five separate studies, one third to one half of OCCs cited system-level factors, including lack of time and resources, as barriers to providing TUT [21-23, 27, 31, 32] . Some OCCs were also unsure where to refer patients or were unaware of community resources such as free quitlines [22, 23, 25] . In their quality improvement initiative, Ma and colleagues discovered only 13% of OCCs were aware of tobacco cessation resources prior to intervention [31] . Warren and colleagues also found that practice setting predicted provision of tobacco treatment. Compared with academic/university settings, clinicians practicing in nonacademic/hospital-based environments were significantly less likely to ask patients about tobacco use or advise them to quit [32] . In a survey of NCI-designated cancer centers, those with an "in-house" TUT program had better communication between providers, and point-persons emerged at these centers who made TUT a major part of their professional role [6] . Cancer center representatives surveyed about factors that would improve TUT most commonly endorsed stable funding, tobacco treatment specialists, space, training for staff, technical assistance for system enhancements, support from physicians, links to resources, and support from administration [6] .
Interventions to Improve Adherence to 5As in Oncology Settings
Although delivery of the 5As in the oncologic context is a clearly identified concern, only two included studies examined interventions for OCCs to improve adherence to clinical practice guidelines. A recent project demonstrated the effectiveness of a brief educational intervention, which included a 10-minute TUT presentation for providers, distribution of a tobacco cessation "teaching sheet" with cancer-specific reasons to quit smoking and a list of available community resources, placement of reminder signs in clinic rooms to alert OCCs to counsel patients about smoking cessation, and the introduction of an EHR template to facilitate tobacco use documentation and discussion at every visit [31] . Prior to the intervention, tobacco use status was recorded only during initial visits, but the process was modified so that it was assessed during vital sign collection at every visit. Five months after intervention, tobacco use discussion documentation increased from 28% to 56%, all head and neck OCCs could name at least one TUT resource in the community, and 88% of OCCs noted that the intervention prompted them to discuss tobacco cessation with their patients [31] . Gosselin and colleagues also tested the effect of a 1-hour education session for OCCs treating head and neck cancer patients and found that the intervention significantly increased the number of patients who were asked about their smoking status, prescribed cessation medications, and received cessation support calls [24] .
LIMITATIONS
The results of this review must be considered in the context of its potential limitations. These include the use of one initial rater instead of multiple data extractors and lack of consultation with a medical librarian [18] . Although all study authors were experienced in conducting rigorous reviews and were actively involved in the search process, these potential limitations should be considered in the context of emerging guidelines on conduct of scoping reviews [33] .
DISCUSSION
This review addresses the persistence of suboptimal tobacco assessment, referral, and treatment patterns in the oncology setting. It also highlights the need to address barriers, clarify roles within multidisciplinary cancer care teams, and develop scalable interventions to improve and sustain adherence to clinical practice guidelines, including the 5As/AAR.
The reviewed studies indicate that OCCs routinely implement the first two As (ask and advise) at patients' initial visit, but that the last three As (assess, assist, arrange) are delivered at much lower rates (<50%). Lack of training was identified as a primary barrier to referring and offering evidence-based tobacco treatments. Although tobacco use intervention has been increasingly integrated into medical school curriculums, practicing OCCs may also require additional instruction [20] . It is important to note that stigma and nihilism may play an insidious role in the quality and frequency of TUT delivery [34] . Therefore, efforts to train OCCs should emphasize compassionate, evidence-based 5A delivery, including Motivational Interviewing principles [35, 36] . The AAR model may be a better alternative to the 5As for OCCs who do not have training in direct cessation interventions. Educational efforts should extend beyond physician training alone; guidelines recommend that all clinicians who have contact with patients implement the 5A model, extending the clinical responsibility for TUT to the entire team of individuals providing cancer care. Being advised to quit by more than one type of health professional increases cessation attempts and readiness to quit [37] . Because nicotine dependence is by nature a relapsing,
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System-level changes are also needed, and any systemlevel efforts will require active participation by clinicians, insurers, and institutions. One important area of focus includes comparing different models for delivering TUT in oncology settings to elucidate preferred roles and opportunities for engagement (e.g., comparing in-house with external referrals or warm handoffs with automatic referrals). More research is also needed to better understand and address differences in adherence to TUT guidelines based on practice setting. Although promising strategies (e.g., dedicating a specialist or "champion" to provide TUT, standardizing systems to identify tobacco users) have been employed at several model cancer centers, the literature has not yet identified one program format that is superior, and different models may be necessary for various cancer care settings. Future research should compare or combine lessons learned from these implementation efforts and include evaluation measures such as cessation outcomes, service uptake, and cost-per-patient [9, 38] . Although NCI's Cancer Moonshot-driven effort to facilitate integration of tobacco treatment into oncology settings at NCI-designated cancer centers is primarily a service implementation initiative, this effort may generate program evaluation data that could provide a broader roadmap for service integration.
CONCLUSION
Recent interventions have reduced burden on the provider in delivering TUT, including the use of prompts within EHRs and automated referrals and follow-up [39] [40] [41] . For example, one site integrated standardized tobacco assessment questions into the EHR to ensure patients were asked at each visit and automatic referrals to a dedicated tobacco cessation program were generated for current users and recent quitters [41] . Physicians had a minimal role in this process but were notified if patients required a prescription for a tobacco cessation medication. Automated support services such as interactive voice response telephone calls provide additional assessment and follow-up points at a low cost and can generate opportunities for referral beyond the confines of the clinic visit.
Clinical reminders and decision support systems within the EHR can also reduce clinician burden in providing TUT. These systems have been implemented in a variety of settings to improve adherence to TUT guidelines and are cost-effective, sustainable, feasible, and acceptable [42] [43] [44] [45] [46] . . Computerized clinical reminders increase the likelihood of documentation, engagement in counseling, and medication prescriptions, and they require minimal training to implement [47] . However, these electronic interventions have limitations, such as clinician pop-up fatigue, and they may need to include embedded strategies to increase clinicians' motivation for use, such as generation of feedback reports [48] . Mobile health technology and targeting of household members and social support systems may also extend the impact of traditional behavioral support and pharmacotherapy cessation strategies. Although these strategies can reduce clinician burden, providers are a trusted source of advice and support during treatment and their role in TUT will remain important.
